Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Pishvaian Discusses Results of Entrectinib in Metastatic Pancreas Cancer

Michael Pishvaian, MD, PhD
Published: Friday, Jan 19, 2018



Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.

The clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions was evaluated in a study presented at the 2018 Gastrointestinal Cancers Symposium. As response rates for this disease loom at 50%, investigators sought to target a distinct molecular subgroup that harbor actionable molecular alterations.

A 600 mg dose of entrectinib were given daily to 3 patients with pancreas cancer—2 with TRP-NTRK gene fusions, and 1 with SCL4-ROS1 gene fusion. Results showed that entrectinib was associated with response and prolonged disease control in all 3 patients. Additionally, all 3 patients had an improvement in quality of life while on the study, Pishvaian says.

<<< View more from the 2018 GI Cancer Symposium


Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.

The clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions was evaluated in a study presented at the 2018 Gastrointestinal Cancers Symposium. As response rates for this disease loom at 50%, investigators sought to target a distinct molecular subgroup that harbor actionable molecular alterations.

A 600 mg dose of entrectinib were given daily to 3 patients with pancreas cancer—2 with TRP-NTRK gene fusions, and 1 with SCL4-ROS1 gene fusion. Results showed that entrectinib was associated with response and prolonged disease control in all 3 patients. Additionally, all 3 patients had an improvement in quality of life while on the study, Pishvaian says.

<<< View more from the 2018 GI Cancer Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x